Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients (original) (raw)

Abstract

A gold standard diagnostic for Clostridioides difficile infection (CDI) does not exist. An area of controversy is how to manage patients whose stool tests positive by nucleic acid amplification tests but negative by toxin enzyme immunoassay.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (46)

  1. change between vancomycin and placebo groups were determined using a Student's t test and corrected for multiple testing using the Holm-Sidak method. For visualization of metagenomics data and computation of community diversity statistics, the packages phyloseq and vegan were used in R. For visualization of heatmaps concerning AST/ARG profiles, the package pheatmap was used. All other statis- tical tests are described in the figure legends. Data availability. All genomic sequences and metagenomics sequences were deposited in NCBI under BioProject no. PRJNA646752. SUPPLEMENTAL MATERIAL Supplemental material is available online only. TEXT S1, DOCX file, 0.03 MB. FIG S1, PDF file, 0.7 MB. FIG S2, PDF file, 0.7 MB. FIG S3, PDF file, 0.8 MB. FIG S4, PDF file, 0.3 MB. TABLE S1, XLSX file, 0.01 MB. TABLE S2, XLSX file, 0.01 MB. TABLE S3, XLSX file, 0.1 MB. TABLE S4, XLSX file, 0.03 MB. TABLE S5, XLSX file, 0.01 MB.
  2. Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, Karlsson M, Gerding DN, McDonald LC, Emerging Infections Program Clostridioides dif- ficile Infection Working Group. 2020. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 382:1320-1330. https://doi .org/10.1056/NEJMoa1910215.
  3. Eze P, Balsells E, Kyaw MH, Nair H. 2017. Risk factors for Clostridium difficile infections-an overview of the evidence base and challenges in data synthe- sis. J Glob Health 7:010417. https://doi.org/10.7189/jogh.07.010417.
  4. Sohn KM, Peck KR, Joo EJ, Ha YE, Kang CI, Chung DR, Lee NY, Song JH. 2013. Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital. Int J Infect Dis 17:e240-e246. https://doi.org/10.1016/j.ijid.2012.09.019.
  5. Cassone M, Mody L. 2015. Colonization with multi-drug resistant organ- isms in nursing homes: scope, importance, and management. Curr Geriatr Rep 4:87-95. https://doi.org/10.1007/s13670-015-0120-2.
  6. Gerding DN, Muto CA, Owens RC, Jr. 2008. Measures to control and pre- vent Clostridium difficile infection. Clin Infect Dis 46(Suppl 1):S43-S49. https://doi.org/10.1086/521861.
  7. Martin JS, Monaghan TM, Wilcox MH. 2016. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gas- troenterol Hepatol 13:206-216. https://doi.org/10.1038/nrgastro.2016.25.
  8. Burnham CA, Carroll KC. 2013. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev 26:604-630. https://doi.org/10.1128/CMR.00016-13.
  9. Koo HL, Van JN, Zhao M, Ye X, Revell PA, Jiang ZD, Grimes CZ, Koo DC, Lasco T, Kozinetz CA, Garey KW, DuPont HL. 2014. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile coloniza- tion and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol 35:667-673. https://doi.org/10.1086/676433.
  10. Zou J, Leung V, Champagne S, Hinch M, Wong A, Lloyd-Smith E, Nguyen TT, Romney MG, Sharma A, Payne M, Lowe CF. 2018. Clinical heterogene- ity of patients with stool samples testing PCR1/Tox-from a two-step Clostridium difficile diagnostic algorithm. Eur J Clin Microbiol Infect Dis 37:2355-2359. https://doi.org/10.1007/s10096-018-3383-7.
  11. Buckel WR, Avdic E, Carroll KC, Gunaseelan V, Hadhazy E, Cosgrove SE. 2015. Gut check: Clostridium difficile testing and treatment in the molec- ular testing era. Infect Control Hosp Epidemiol 36:217-221. https://doi .org/10.1017/ice.2014.19.
  12. Chiu CY, Sarwal A, Feinstein A, Hennessey K. 2019. Effective dosage of oral vancomycin in treatment for initial episode of Clostridioides difficile infection: a systematic review and meta-analysis. Antibiotics (Basel) 8:173. https://doi.org/10.3390/antibiotics8040173.
  13. Sayedy L, Kothari D, Richards RJ. 2010. Toxic megacolon associated Clos- tridium difficile colitis. World J Gastrointest Endosc 2:293-297. https://doi .org/10.4253/wjge.v2.i8.293.
  14. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. 1992. Treatment of asymptomatic Clostridium difficile car- riers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 117:297-302. https://doi.org/10 .7326/0003-4819-117-4-297.
  15. MacPherson CW, Mathieu O, Tremblay J, Champagne J, Nantel A, Girard SA, Tompkins TA. 2018. Gut bacterial microbiota and its resistome rapidly recover to basal state levels after short-term amoxicillin-clavulanic acid treatment in healthy adults. Sci Rep 8:11192. https://doi.org/10.1038/ s41598-018-29229-5.
  16. Li J, Rettedal EA, van der Helm E, Ellabaan M, Panagiotou G, Sommer MOA. 2019. Antibiotic treatment drives the diversification of the human gut resistome. Genomics Proteomics Bioinformatics 17:39-51. https://doi .org/10.1016/j.gpb.2018.12.003.
  17. Yamaguchi T, Konishi H, Aoki K, Ishii Y, Chono K, Tateda K. 2020. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. J Infect Chemother 26:483-491. https://doi.org/10.1016/j.jiac.2019.12.020.
  18. Sethi AK, Al-Nassir WN, Nerandzic MM, Donskey CJ. 2009. Skin and envi- ronmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 30:13-17. https://doi.org/10.1086/592710.
  19. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. 2008. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium dif- ficile-associated disease. Antimicrob Agents Chemother 52:2403-2406. https://doi.org/10.1128/AAC.00090-08.
  20. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ. 2008. Emergence of Clostridium dif- ficile infection due to a new hypervirulent strain, polymerase chain reac- tion ribotype 078. Clin Infect Dis 47:1162-1170. https://doi.org/10.1086/ 592257.
  21. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. 2012. Reduced acquisition and overgrowth of vancomycin-resistant entero- cocci and Candida species in patients treated with fidaxomicin versus van- comycin for Clostridium difficile infection. Clin Infect Dis 55:S121-S126. https://doi.org/10.1093/cid/cis440.
  22. McElvania Tekippe E, Shuey S, Winkler DW, Butler MA, Burnham CA. 2013. Optimizing identification of clinically relevant Gram-positive organisms by use of the Bruker Biotyper matrix-assisted laser desorption ionization- time of flight mass spectrometry system. J Clin Microbiol 51:1421-1427. https://doi.org/10.1128/JCM.02680-12.
  23. Hill CM, Krause KM, Lewis SR, Blais J, Benton BM, Mammen M, Humphrey PP, Kinana A, Janc JW. 2010. Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin. Antimicrob Agents Chemother 54:2814-2818. https://doi.org/10.1128/AAC.01737-09.
  24. Cui Y, Dong D, Zhang L, Wang D, Jiang C, Ni Q, Wang C, Mao E, Peng Y. 2019. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China. BMC Infect Dis 19:961. https://doi.org/10.1186/s12879-019-4603-1.
  25. Pilate T, Verhaegen J, Van Ranst M, Saegeman V. 2016. Binary toxin and its clinical importance in Clostridium difficile infection, Belgium. Eur J Clin Microbiol Infect Dis 35:1741-1747. https://doi.org/10.1007/s10096-016 -2719-4.
  26. Stewart DB, Berg A, Hegarty J. 2013. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastroint- est Surg 17:118-124. https://doi.org/10.1007/s11605-012-2056-6.
  27. Knetsch CW, Connor TR, Mutreja A, van Dorp SM, Sanders IM, Browne HP, Harris D, Lipman L, Keessen EC, Corver J, Kuijper EJ, Lawley TD. 2014. Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands, 2002 to 2011. Euro Surveill 19:20954. https://doi.org/10.2807/1560-7917.es2014.19.45.20954.
  28. Johnson SW, Brown SV, Priest DH. 2019. Effectiveness of oral vancomycin for prevention of healthcare facility-onset Clostridioides difficile infection in targeted patients during systemic antibiotic exposure. Clin Infect Dis 71:1133-1139. https://doi.org/10.1093/cid/ciz966.
  29. D'Souza AW, Potter RF, Wallace M, Shupe A, Patel S, Sun X, Gul D, Kwon JH, Andleeb S, Burnham CD, Dantas G. 2019. Spatiotemporal dynamics of multidrug resistant bacteria on intensive care unit surfaces. Nat Commun 10:4569. https://doi.org/10.1038/s41467-019-12563-1.
  30. Hink T, Burnham CA, Dubberke ER. 2013. A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens. Anaerobe 19:39-43. https://doi.org/10.1016/j.anaerobe .2012.12.001.
  31. Westblade LF, Chamberland RR, MacCannell D, Collins R, Dubberke ER, Dunne WM, Jr, Burnham CA. 2013. Development and evaluation of a novel, semiautomated Clostridium difficile typing platform. J Clin Micro- biol 51:621-624. https://doi.org/10.1128/JCM.02627-12.
  32. Zhou Y, Burnham CA, Hink T, Chen L, Shaikh N, Wollam A, Sodergren E, Weinstock GM, Tarr PI, Dubberke ER. 2014. Phenotypic and genotypic analysis of Clostridium difficile isolates: a single-center study. J Clin Micro- biol 52:4260-4266. https://doi.org/10.1128/JCM.02115-14.
  33. D'Souza AW, Moodley-Govender E, Berla B, Kelkar T, Wang B, Sun X, Daniels B, Coutsoudis A, Trehan I, Dantas G. 2019. Cotrimoxazole prophylaxis increases resistance gene prevalence and alpha-diversity but decreases beta-diversity in the gut microbiome of HIV-exposed uninfected infants. Clin Infect Dis 13:ciz1186. https://doi.org/10.1093/cid/ciz1186.
  34. Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C. 2012. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods 9:811-814. https://doi.org/10 .1038/nmeth.2066.
  35. Kaminski J, Gibson MK, Franzosa EA, Segata N, Dantas G, Huttenhower C. 2015. High-specificity targeted functional profiling in microbial commun- ities with ShortBRED. PLoS Comput Biol 11:e1004557. https://doi.org/10 .1371/journal.pcbi.1004557.
  36. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, Bhullar K, Canova MJ, De Pascale G, Ejim L, Kalan L, King AM, Koteva K, Morar M, Mulvey MR, O'Brien JS, Pawlowski AC, Piddock LJ, Spanogiannopoulos P, Sutherland AD, Tang I, Taylor PL, Thaker M, Wang W, Yan M, Yu T, Wright GD. 2013. The comprehensive antibiotic resistance database. Antimicrob Agents Chemother 57:3348-3357. https://doi.org/10.1128/AAC.00419-13.
  37. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new ge- nome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455-477. https://doi.org/10.1089/cmb.2012.0021.
  38. Gurevich A, Saveliev V, Vyahhi N, Tesler G. 2013. QUAST: quality assessment tool for genome assemblies. Bioinformatics 29:1072-1075. https://doi.org/ 10.1093/bioinformatics/btt086.
  39. Takada K, Ono Y. 1989. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 63:445-449. https://doi.org/ 10.1128/JVI.63.1.445-449.1989.
  40. Asherson GL, Colizzi V, Zembala M, James BB, Watkins MC. 1984. Nonspecific inhibitor of contact sensitivity made by T-acceptor cells: triggering of T cells armed with antigen-specific T-suppressor factor (TsF) requires both occu- pancy of the major histocompatibility complex recognition site by soluble I-J product and cross-linking of the antigen recognition sites of the TsF. Cell Immunol 83:389-397. https://doi.org/10.1016/0008-8749(84)90318-6.
  41. Price MN, Dehal PS, Arkin AP. 2010. FastTree 2-approximately maximum- likelihood trees for large alignments. PLoS One 5:e9490. https://doi.org/ 10.1371/journal.pone.0009490.
  42. Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: recent updates Vancomycin Treatment and C. difficile Colonization January/February 2021 Volume 6 Issue 1 e00936-20 msphere.asm.org 11
  43. Downloaded from https://journals.asm.org/journal/msphere on 23 October 2021 by 3.238.29.207. and new developments. Nucleic Acids Res 47:W256-W259. https://doi .org/10.1093/nar/gkz239.
  44. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu CH, McDermott PF, Tadesse DA, Morales C, Simmons M, Tillman G, Wasilenko J, Folster JP, Klimke W. 2019. Validating the AMR- Finder tool and resistance gene database by using antimicrobial resistance genotype-phenotype correlations in a collection of isolates. Antimicrob Agents Chemother 63:e00483-19. https://doi.org/10.1128/AAC.00483-19.
  45. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, Harris SR. 2016. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments. Microb Genom 2:e000056. https://doi.org/10.1099/mgen.0 .000056.
  46. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. Bioinfor- matics 25:2078-2079. https://doi.org/10.1093/bioinformatics/btp352.